Rituximab in the treatment of alloimmune factor VIII and IX antibodies in two children with severe haemophilia


Ri Liesner, Consultant Haematologist, Haemophilia Centre Great Ormond Street Children's Hospital, Great Ormond Street, London WC1N 3JH, UK.
E-mail: liesnr@gosh.nhs.uk


We report the use of rituximab (Genentech, San Francisco, CA, USA) in two children with severe haemophilia with inhibitors to factors VIII and IX, which failed to respond to conventional immune tolerance therapy. The treatment was well tolerated by both children. The child with haemophilia B had no clinical improvement or fall in CD19 and he is currently being treated with recombinant activated factor VII (NovoSeven, Novo Nordisk, Denmark) for bleeding episodes. The child with haemophilia A had a good clinical response with a negative inhibitor assay at 11 months follow-up.